Eli Lilly price target lowered to $970 from $1,000 at Wells Fargo
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
MarketBeat on MSN15h
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
i6h
Britons face paying more for weight-loss jabs... to make them cheaper for Americans
Anti-obesity drug Mounjaro is set rack up sales of nearly £22bn a year by 2030. But Trump's 'America First' policies mean Britons could soon be paying more for the 'King Kong' of weight-loss jabs ...
Barchart on MSN8h
This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.
Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...
Serial biotech entrepreneur targets obesity with drug fished out of bankruptcy court
A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...
KVIA20h
Mounjaro menu plan: What foods to eat and avoid for optimal results
Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...